The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease

Current Medicinal Chemistry

Volumn 18, Issue 31, 2011, Pages 4813-4819

  Grigoropoulou, P ^a   Eleftheriadou, I ^a   Zoupas, C ^a   Tentolouris, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Arterial calcification; Atherosclerosis; Diabetes; OPG; Osteoprotegerin; RANK; RANKL; Vascular disease

Indexed keywords

HEMOGLOBIN A1C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA;

ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; VASCULAR DISEASES;

EID: 80054860629     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797535281     Document Type: Article

References (108)

1. Dent, T.H. Predicting the risk of coronary heart disease. II: The role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. Atherosclerosis, 2010, 213, 352-362.
2. Ross, R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
3. Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.S.; Luthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; Colombero, A.; Tan, H.L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T.M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; Tarpley, J.; Derby, P.; Lee, R.; Boyle, W.J. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 1997, 89, 309-319. (Pubitemid 27199902)
4. Tsuda, E.; Goto, M.; Mochizuki, S.; Yano, K.; Kobayashi, F.; Morinaga, T.; Higashio, K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 1997, 234, 137-142. (Pubitemid 27267548)
5. Yasuda, H.; Shima, N.; Nakagawa, N.; Mochizuki, S.I.; Yano, K.; Fujise, N.; Sato, Y.; Goto, M.; Yamaguchi, K.; Kuriyama, M.; Kanno, T.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 1998, 139, 1329-1337. (Pubitemid 28510154)
6. Dhore, C.R.; Cleutjens, J.P.; Lutgens, E.; Cleutjens, K.B.; Geusens, P.P.; Kitslaar, P.J.; Tordoir, J.H.; Spronk, H.M.; Vermeer, C.; Daemen, M.J. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 2001, 21, 1998-2003. (Pubitemid 34219753)
7. Tan, K.B.; Harrop, J.; Reddy, M.; Young, P.; Terrett, J.; Emery, J.; Moore, G.; Truneh, A. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells. Gene, 1997, 204, 35-46. (Pubitemid 28022168)
8. Yun, T.J.; Chaudhary, P.M.; Shu, G.L.; Frazer, J.K.; Ewings, M.K.; Schwartz, S.M.; Pascual, V.; Hood, L.E.; Clark, E.A. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol, 1998, 161, 6113-6121. (Pubitemid 28535982)
9. Hofbauer, L.C.; Khosla, S.; Dunstan, C.R.; Lacey, D.L.; Boyle, W.J.; Riggs, B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res, 2000, 15, 2-12. (Pubitemid 30026926)
10. Hofbauer, L.C.; Dunstan, C.R.; Spelsberg, T.C.; Riggs, B.L.; Khosla, S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun, 1998, 250, 776-781. (Pubitemid 28484803)
11. Palmqvist, P.; Lundberg, P.; Persson, E.; Johansson, A.; Lundgren, I.; Lie, A.; Conaway, H.H.; Lerner, U.H. Inhibition of hormone and cytokinestimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem, 2006, 281, 2414-2429. (Pubitemid 43845701)
12. Palmqvist, P.; Persson, E.; Conaway, H.H.; Lerner, U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol, 2002, 169, 3353-3362. (Pubitemid 35013185)
13. Takai, H.; Kanematsu, M.; Yano, K.; Tsuda, E.; Higashio, K.; Ikeda, K.; Watanabe, K.; Yamada, Y. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem, 1998, 273, 27091-27096. (Pubitemid 28500414)
14. Hofbauer, L.C.; Khosla, S.; Dunstan, C.R.; Lacey, D.L.; Spelsberg, T.C.; Riggs, B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 1999, 140, 4367-4370. (Pubitemid 30647136)
15. Vidal, N.O.; Brandstrom, H.; Jonsson, K.B.; Ohlsson, C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: D own-regulation by glucocorticoids. J Endocrinol, 1998, 159, 191-195. (Pubitemid 28459282)
16. Hofbauer, L.C.; Gori, F.; Riggs, B.L.; Lacey, D.L.; Dunstan, C.R.; Spelsberg, T.C.; Khosla, S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoidinduced osteoporosis. Endocrinology, 1999, 140, 4382-4389. (Pubitemid 30666099)
17. Hofbauer, L.C.; Shui, C.; Riggs, B.L.; Dunstan, C.R.; Spelsberg, T.C.; O'Brien, T.; Khosla, S. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun, 2001, 280, 334-339. (Pubitemid 32917516)
18. Brandstrom, H.; Jonsson, K.B.; Ohlsson, C.; Vidal, O.; Ljunghall, S.; Ljunggren, O. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun, 1998, 247, 338-341. (Pubitemid 28420824)
19. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K.; Udagawa, N.; Takahashi, N.; Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A, 1998, 95, 3597-3602.
20. Lacey, D.L.; Timms, E.; Tan, H.L.; Kelley, M.J.; Dunstan, C.R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; Hsu, H.; Sullivan, J.; Hawkins, N.; Davy, E.; Capparelli, C.; Eli, A.; Qian, Y.X.; Kaufman, S.; Sarosi, I.; Shalhoub, V.; Senaldi, G.; Guo, J.; Delaney, J.; Boyle, W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93, 165-176. (Pubitemid 28180851)
21. Anderson, D.M.; Maraskovsky, E.; Billingsley, W.L.; Dougall, W.C.; Tometsko, M.E.; Roux, E.R.; Teepe, M.C.; DuBose, R.F.; Cosman, D.; Galibert, L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390, 175-179. (Pubitemid 27507987)
22. Hsu, H.; Lacey, D.L.; Dunstan, C.R.; Solovyev, I.; Colombero, A.; Timms, E.; Tan, H.L.; Elliott, G.; Kelley, M.J.; Sarosi, I.; Wang, L.; Xia, X.Z.; Elliott, R.; Chiu, L.; Black, T.; Scully, S.; Capparelli, C.; Morony, S.; Shimamoto, G.; Bass, M.B.; Boyle, W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A, 1999, 96, 3540-3545. (Pubitemid 29168945)
23. Kong, Y.Y.; Boyle, W.J.; Penninger, J.M. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol, 1999, 77, 188-193. (Pubitemid 29167060)
24. Schoppet, M.; Preissner, K.T.; Hofbauer, L.C. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol, 2002, 22, 549-553. (Pubitemid 34408732)
25. Emery, J.G.; McDonnell, P.; Burke, M.B.; Deen, K.C.; Lyn, S.; Silverman, C.; Dul, E.; Appelbaum, E.R.; Eichman, C.; DiPrinzio, R.; Dodds, R.A.; James, I.E.; Rosenberg, M.; Lee, J.C.; Young, P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 1998, 273, 14363-14367. (Pubitemid 28319153)
26. Reid, P.; Holen, I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol, 2009, 88, 1-17.
27. Bucay, N.; Sarosi, I.; Dunstan, C.R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H.L.; Xu, W.; Lacey, D.L.; Boyle, W.J.; Simonet, W.S. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998, 12, 1260-1268. (Pubitemid 28213402)
28. Min, H.; Morony, S.; Sarosi, I.; Dunstan, C.R.; Capparelli, C.; Scully, S.; Van, G.; Kaufman, S.; Kostenuik, P.J.; Lacey, D.L.; Boyle, W.J.; Simonet, W.S. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med, 2000, 192, 463-474. (Pubitemid 30666247)
29. Price, P.A.; June, H.H.; Buckley, J.R.; Williamson, M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol, 2001, 21, 1610-1616. (Pubitemid 34215580)
30. Bennett, B.J.; Scatena, M.; Kirk, E.A.; Rattazzi, M.; Varon, R.M.; Averill, M.; Schwartz, S.M.; Giachelli, C.M.; Rosenfeld, M.E. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol, 2006, 26, 2117-2124. (Pubitemid 44253797)
31. Morony, S.; Tintut, Y.; Zhang, Z.; Cattley, R.C.; Van, G.; Dwyer, D.; Stolina, M.; Kostenuik, P.J.; Demer, L.L. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation, 2008, 117, 411-420.
32. Collin-Osdoby, P.; Rothe, L.; Anderson, F.; Nelson, M.; Maloney, W.; Osdoby, P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem, 2001, 276, 20659-20672.
33. Ueland, T.; Yndestad, A.; Oie, E.; Florholmen, G.; Halvorsen, B.; Froland, S.S.; Simonsen, S.; Christensen, G.; Gullestad, L.; Aukrust, P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation, 2005, 111, 2461-2468. (Pubitemid 40696134)
34. Browner, W.S.; Lui, L.Y.; Cummings, S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab, 2001, 86, 631-637. (Pubitemid 32207471)
35. Kiechl, S.; Schett, G.; Wenning, G.; Redlich, K.; Oberhollenzer, M.; Mayr, A.; Santer, P.; Smolen, J.; Poewe, W.; Willeit, J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 2004, 109, 2175-2180. (Pubitemid 38625393)
36. Ueland, T.; Jemtland, R.; Godang, K.; Kjekshus, J.; Hognestad, A.; Omland, T.; Squire, I.B.; Gullestad, L.; Bollerslev, J.; Dickstein, K.; Aukrust, P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol, 2004, 44, 1970-1976. (Pubitemid 39473280)
37. Lieb, W.; Gona, P.; Larson, M.G.; Massaro, J.M.; Lipinska, I.; Keaney, J.F., Jr.; Rong, J.; Corey, D.; Hoffmann, U.; Fox, C.S.; Vasan, R.S.; Benjamin, E.J.; O'Donnell, C.J.; Kathiresan, S. Biomarkers of the osteoprotegerin pathway: C linical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol, 2010, 30, 1849-1854.
38. Schoppet, M.; Sattler, A.M.; Schaefer, J.R.; Herzum, M.; Maisch, B.; Hofbauer, L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 2003, 88, 1024-1028. (Pubitemid 36337751)
39. Schoppet, M.; Schaefer, J.R.; Hofbauer, L.C. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation, 2003, 107, e76; author reply e76.
40. Jono, S.; Ikari, Y.; Shioi, A.; Mori, K.; Miki, T.; Hara, K.; Nishizawa, Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002, 106, 1192-1194. (Pubitemid 34988634)
41. Rhee, E.J.; Lee, W.Y.; Kim, S.Y.; Kim, B.J.; Sung, K.C.; Kim, B.S.; Kang, J.H.; Oh, K.W.; Oh, E.S.; Baek, K.H.; Kang, M.I.; Woo, H.Y.; Park, H.S.; Kim, S.W.; Lee, M.H.; Park, J.R. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond), 2005, 108, 237-243.
42. Crisafulli, A.; Micari, A.; Altavilla, D.; Saporito, F.; Sardella, A.; Passaniti, M.; Raffa, S.; D'Anneo, G.; Luca, F.; Mioni, C.; Arrigo, F.; Squadrito, F. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond), 2005, 109, 389-395. (Pubitemid 41445246)
43. Asanuma, Y.; Chung, C.P.; Oeser, A.; Solus, J.F.; Avalos, I.; Gebretsadik, T.; Shintani, A.; Raggi, P.; Sokka, T.; Pincus, T.; Stein, C.M. Serum osteoprotegerin is increased and independently associated with coronaryartery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis, 2007, 195, e135-141. (Pubitemid 350087969)
44. Abedin, M.; Omland, T.; Ueland, T.; Khera, A.; Aukrust, P.; Murphy, S.A.; Jain, T.; Gruntmanis, U.; McGuire, D.K.; de Lemos, J.A. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol, 2007, 99, 513-518. (Pubitemid 46215559)
45. Ziegler, S.; Kudlacek, S.; Luger, A.; Minar, E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis, 2005, 182, 175-180. (Pubitemid 41188384)
46. Koshikawa, M.; Aizawa, K.; Kasai, H.; Izawa, A.; Tomita, T.; Kumazaki, S.; Tsutsui, H.; Koyama, J.; Shimodaira, S.; Takahashi, M.; Ikeda, U. Elevated osteopontin levels in patients with peripheral arterial disease. Angiology, 2009, 60, 42-45.
47. Pennisi, P.; Signorelli, S.S.; Riccobene, S.; Celotta, G.; Di Pino, L.; La Malfa, T.; Fiore, C.E. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int, 2004, 15, 389-395. (Pubitemid 38639334)
48. Szulc, P.; Hofbauer, L.C.; Heufelder, A.E.; Roth, S.; Delmas, P.D. Osteoprotegerin serum levels in men: C orrelation with age, estrogen, and testosterone status. J Clin Endocrinol Metab, 2001, 86, 3162-3165. (Pubitemid 32673481)
49. Rasmussen, L.M.; Tarnow, L.; Hansen, T.K.; Parving, H.H.; Flyvbjerg, A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol, 2006, 154, 75-81. (Pubitemid 43250739)
50. Shin, J.Y.; Shin, Y.G.; Chung, C.H. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care, 2006, 29, 1664-1666.
51. Kim, S.M.; Lee, J.; Ryu, O.H.; Lee, K.W.; Kim, H.Y.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Baik, S.H.; Choi, D.S.; Choi, K.M. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf), 2005, 63, 594-598. (Pubitemid 41626757)
52. Xiang, G.D.; Xu, L.; Zhao, L.S.; Yue, L.; Hou, J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 2006, 55, 2126-2131. (Pubitemid 44509988)
53. Kazama, J.J.; Shigematsu, T.; Yano, K.; Tsuda, E.; Miura, M.; Iwasaki, Y.; Kawaguchi, Y.; Gejyo, F.; Kurokawa, K.; Fukagawa, M. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis, 2002, 39, 525-532. (Pubitemid 34194628)
54. Knudsen, S.T.; Foss, C.H.; Poulsen, P.L.; Andersen, N.H.; Mogensen, C.E.; Rasmussen, L.M. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol, 2003, 149, 39-42. (Pubitemid 36874202)
55. Galluzzi, F.; Stagi, S.; Salti, R.; Toni, S.; Piscitelli, E.; Simonini, G.; Falcini, F.; Chiarelli, F. Osteoprotegerin serum levels in children with type 1 diabetes: A potential modulating role in bone status. Eur J Endocrinol, 2005, 153, 879-885. (Pubitemid 43020239)
56. Avignon, A.; Sultan, A.; Piot, C.; Elaerts, S.; Cristol, J.P.; Dupuy, A.M. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care, 2005, 28, 2176-2180. (Pubitemid 41242464)
57. Nabipour, I.; Kalantarhormozi, M.; Larijani, B.; Assadi, M.; Sanjdideh, Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism, 2010, 59, 742-747.
58. Secchiero, P.; Corallini, F.; Pandolfi, A.; Consoli, A.; Candido, R.; Fabris, B.; Celeghini, C.; Capitani, S.; Zauli, G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol, 2006, 169, 2236-2244. (Pubitemid 351181981)
59. Avignon, A.; Sultan, A.; Piot, C.; Mariano-Goulart, D.; Thuan Dit Dieudonne, J.F.; Cristol, J.P.; Dupuy, A.M. Osteoprotegerin: A novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care, 2007, 30, 2934-2939. (Pubitemid 350083147)
60. Anand, D.V.; Lahiri, A.; Lim, E.; Hopkins, D.; Corder, R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol, 2006, 47, 1850-1857.
61. Anand, D.V.; Lim, E.; Darko, D.; Bassett, P.; Hopkins, D.; Lipkin, D.; Corder, R.; Lahiri, A. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol, 2007, 50, 2218-2225. (Pubitemid 350166815)
62. Budoff, M.J.; Achenbach, S.; Blumenthal, R.S.; Carr, J.J.; Goldin, J.G.; Greenland, P.; Guerci, A.D.; Lima, J.A.; Rader, D.J.; Rubin, G.D.; Shaw, L.J.; Wiegers, S.E. Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation, 2006, 114, 1761-1791. (Pubitemid 44607126)
63. Jung, C.H.; Lee, W.Y.; Kim, S.Y.; Jung, J.H.; Rhee, E.J.; Park, C.Y.; Mok, J.O.; Oh, K.W.; Kim, C.H.; Park, S.W.; Kim, S.W. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol, 2009.
64. Ishiyama, M.; Suzuki, E.; Katsuda, J.; Murase, H.; Tajima, Y.; Horikawa, Y.; Goto, S.; Fujita, T.; Takeda, J. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract, 2009, 85, 189-196.
65. Xiang, G.D.; Pu, J.H.; Zhao, L.S.; Sun, H.L.; Hou, J.; Yue, L. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med, 2009, 26, 397-403.
66. Terekeci, H.M.; Senol, M.G.; Top, C.; Sahan, B.; Celik, S.; Sayan, O.; Kucukardali, Y.; Ipcioglu, O.; Cagiltay, E.; Oktenli, C.; Ozata, M. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes, 2009, 117, 119-123.
67. Nybo, M.; Poulsen, M.K.; Grauslund, J.; Henriksen, J.E.; Rasmussen, L.M. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients. Diabet Med, 2010, 27, 289-294.
68. Cruickshank, K.; Riste, L.; Anderson, S.G.; Wright, J.S.; Dunn, G.; Gosling, R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: A n integrated index of vascular function? Circulation, 2002, 106, 2085-2090. (Pubitemid 35192814)
69. Olesen, P.; Ledet, T.; Rasmussen, L.M. Arterial osteoprotegerin: Increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia, 2005, 48, 561-568. (Pubitemid 40487304)
70. Jorgensen, G.M.; Vind, B.; Nybo, M.; Rasmussen, L.M.; Hojlund, K. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol, 2009, 161, 95-101.
71. Singh, D.K.; Winocour, P.; Summerhayes, B.; Viljoen, A.; Sivakumar, G.; Farrington, K. Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus. Acta Diabetol, 2009.
72. Tintut, Y.; Patel, J.; Parhami, F.; Demer, L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation, 2000, 102, 2636-2642.
73. Barath, P.; Fishbein, M.C.; Cao, J.; Berenson, J.; Helfant, R.H.; Forrester, J.S. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol, 1990, 65, 297-302. (Pubitemid 20038909)
74. Lechleitner, M.; Koch, T.; Herold, M.; Dzien, A.; Hoppichler, F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med, 2000, 248, 67-76. (Pubitemid 30470006)
75. Plomgaard, P.; Nielsen, A.R.; Fischer, C.P.; Mortensen, O.H.; Broholm, C.; Penkowa, M.; Krogh-Madsen, R.; Erikstrup, C.; Lindegaard, B.; Petersen, A.M.; Taudorf, S.; Pedersen, B.K. Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia, 2007, 50, 2562-2571. (Pubitemid 350060651)
76. Nilsson, J.; Jovinge, S.; Niemann, A.; Reneland, R.; Lithell, H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol, 1998, 18, 1199-1202. (Pubitemid 28376175)
77. Duan, S.Z.; Usher, M.G.; Mortensen, R.M. Peroxisome proliferator- activated receptor-gamma-mediated effects in the vasculature. Circ Res, 2008, 102, 283-294. (Pubitemid 351271648)
78. Benson, S.; Wu, J.; Padmanabhan, S.; Kurtz, T.W.; Pershadsingh, H.A. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: Inhibition of growth, migration, and cfos expression by the peroxisome proliferator-activated receptor (PPAR)- gamma activator troglitazone. Am J Hypertens, 2000, 13, 74-82. (Pubitemid 30103867)
79. Marx, N.; Schonbeck, U.; Lazar, M.A.; Libby, P.; Plutzky, J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res, 1998, 83, 1097-1103. (Pubitemid 28533518)
80. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82. (Pubitemid 28079218)
81. Fu, M.; Zhang, J.; Lin Yg, Y.; Zhu, X.; Willson, T.M.; Chen, Y.E. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun, 2002, 294, 597-601. (Pubitemid 34694051)
82. Golledge, J.; McCann, M.; Mangan, S.; Lam, A.; Karan, M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke, 2004, 35, 1636-1641. (Pubitemid 38823639)
83. Sandberg, W.J.; Yndestad, A.; Oie, E.; Smith, C.; Ueland, T.; Ovchinnikova, O.; Robertson, A.K.; Muller, F.; Semb, A.G.; Scholz, H.; Andreassen, A.K.; Gullestad, L.; Damas, J.K.; Froland, S.S.; Hansson, G.K.; Halvorsen, B.; Aukrust, P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: Possible role in plaque destabilization. Arterioscler Thromb Vasc Biol, 2006, 26, 857-863. (Pubitemid 43732163)
84. Doherty, T.M.; Fitzpatrick, L.A.; Inoue, D.; Qiao, J.H.; Fishbein, M.C.; Detrano, R.C.; Shah, P.K.; Rajavashisth, T.B. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev, 2004, 25, 629-672. (Pubitemid 39096073)
85. Niskanen, L.K.; Suhonen, M.; Siitonen, O.; Lehtinen, J.M.; Uusitupa, M.I. Aortic and lower limb artery calcification in type 2 (non-insulin-dependent) diabetic patients and non-diabetic control subjects. A five year follow-up study. Atherosclerosis, 1990, 84, 61-71. (Pubitemid 20267456)
86. Mozes, G.; Keresztury, G.; Kadar, A.; Magyar, J.; Sipos, B.; Dzsinich, S.; Gloviczki, P. Atherosclerosis in amputated legs of patients with and without diabetes mellitus. Int Angiol, 1998, 17, 282-286. (Pubitemid 29126962)
87. Lehto, S.; Niskanen, L.; Suhonen, M.; Ronnemaa, T.; Laakso, M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol, 1996, 16, 978-983. (Pubitemid 26266896)
88. Niskanen, L.; Siitonen, O.; Suhonen, M.; Uusitupa, M.I. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care, 1994, 17, 1252-1256. (Pubitemid 24324967)
89. Gijsbers, B.L.; van Haarlem, L.J.; Soute, B.A.; Ebberink, R.H.; Vermeer, C. Characterization of a Gla-containing protein from calcified human atherosclerotic plaques. Arteriosclerosis, 1990, 10, 991-995.
90. Katsuda, S.; Okada, Y.; Minamoto, T.; Oda, Y.; Matsui, Y.; Nakanishi, I. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb, 1992, 12, 494-502.
91. Bostrom, K.; Watson, K.E.; Horn, S.; Wortham, C.; Herman, I.M.; Demer, L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest, 1993, 91, 1800-1809. (Pubitemid 23127387)
92. Rekhter, M.D.; Zhang, K.; Narayanan, A.S.; Phan, S.; Schork, M.A.; Gordon, D. Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. Am J Pathol, 1993, 143, 1634-1648. (Pubitemid 24058267)
93. Jono, S.; Shioi, A.; Ikari, Y.; Nishizawa, Y. Vascular calcification in chronic kidney disease. J Bone Miner Metab, 2006, 24, 176-181.
94. Hak, A.E.; Pols, H.A.; van Hemert, A.M.; Hofman, A.; Witteman, J.C. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler Thromb Vasc Biol, 2000, 20, 1926-1931. (Pubitemid 30644642)
95. Demer, L.L. A skeleton in the atherosclerosis closet. Circulation, 1995, 92, 2029-2032.
96. Barengolts, E.I.; Berman, M.; Kukreja, S.C.; Kouznetsova, T.; Lin, C.; Chomka, E.V. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int, 1998, 62, 209-213. (Pubitemid 28127932)
97. Uyama, O.; Yoshimoto, Y.; Yamamoto, Y.; Kawai, A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke, 1997, 28, 1730-1732. (Pubitemid 27391440)
98. von der Recke, P.; Hansen, M.A.; Hassager, C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med, 1999, 106, 273-278. (Pubitemid 29153403)
99. van der Klift, M.; Pols, H.A.; Hak, A.E.; Witteman, J.C.; Hofman, A.; de Laet, C.E. Bone mineral density and the risk of peripheral arterial disease: The Rotterdam Study. Calcif Tissue Int, 2002, 70, 443-449. (Pubitemid 36929580)
100. Yano, K.; Tsuda, E.; Washida, N.; Kobayashi, F.; Goto, M.; Harada, A.; Ikeda, K.; Higashio, K.; Yamada, Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res, 1999, 14, 518-527. (Pubitemid 29153384)
101. Hofbauer, L.C.; Schoppet, M. Osteoprotegerin: A link between osteoporosis and arterial calcification? Lancet, 2001, 358, 257-259. (Pubitemid 32738960)
102. Bennett, M.R.; Evan, G.I.; Schwartz, S.M. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest, 1995, 95, 2266-2274.
103. Moran, C.S.; McCann, M.; Karan, M.; Norman, P.; Ketheesan, N.; Golledge, J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation, 2005, 111, 3119-3125. (Pubitemid 40847790)
104. Mangan, S.H.; Van Campenhout, A.; Rush, C.; Golledge, J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res, 2007, 76, 494-505. (Pubitemid 350007458)
105. Zauli, G.; Corallini, F.; Bossi, F.; Fischetti, F.; Durigutto, P.; Celeghini, C.; Tedesco, F.; Secchiero, P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110, 536-543. (Pubitemid 47105391)
106. Min, J.K.; Cho, Y.L.; Choi, J.H.; Kim, Y.; Kim, J.H.; Yu, Y.S.; Rho, J.; Mochizuki, N.; Kim, Y.M.; Oh, G.T.; Kwon, Y.G. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: Impaired permeability and angiogenesis in eNOS-deficient mice. Blood, 2007, 109, 1495-1502. (Pubitemid 46239581)
107. Landmesser, U.; Hornig, B.; Drexler, H. Endothelial function: A critical determinant in atherosclerosis? Circulation, 2004, 109, II27-33. (Pubitemid 38724153)
108. Zannettino, A.C.; Holding, C.A.; Diamond, P.; Atkins, G.J.; Kostakis, P.; Farrugia, A.; Gamble, J.; To, L.B.; Findlay, D.M.; Haynes, D.R. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol, 2005, 204, 714-723. (Pubitemid 40934668)